{
    "symbol": "GTHX",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-02 13:31:10",
    "content": " As Raj will discuss among the clinical milestones that we've reached during the quarter, and since our R&D Day in September, we announced this morning that we are seeing encouraging initial safety results from our Phase 2 ADC trial with sacituzumab govitecan that shows its potential to provide clinically meaningful reductions of over 50% in adverse events related to sacituzumab such as myelosuppression, diarrhea, and potentially even alopecia compared to previously published single agent safety profile of this ADC."
}